According to our new market research study on “Cell Therapy Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Therapy Type, Product, Technology, Application, and End User,” the market is expected to reach US$ 12,563.23 million by 2027 from US$ 7,260.50 million in 2019. It is estimated to grow at a CAGR of 7.2% from 2020–2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. The growth of the market is attributed to increasing prevalence of chronic diseases, rising adoption of regenerative medicines, and surging number of approvals for cell-based therapies. However, the high cost of cell therapy manufacturing hinders the growth of the market.

Get sample PDF Copy of Cell Therapy Market at @ https://www.theinsightpartners.com/sample/TIPRE00009666/

The cell therapy market, by technology, is segmented into viral vector technology, genome editing technology, somatic cell technology, cell immortalization technology, cell plasticity technology, and three-dimensional technology. The viral vector technology segment held the largest share of the market in 2019. Also, the same segment is anticipated to register the highest CAGR in the market during the forecast period.

Regenerative therapies aim to induce regeneration of cells, tissues, and organs and restore their functions. Increasing number of regenerative medicine applications for human clinical trials are submitted to the Food and Drug Administration (FDA) each year. As per the Alliance for Regenerative Medicine, in 2019 (Q3), 1,052 clinical trials utilizing regenerative medicine were underway globally; 218 cellular therapy trials were underway (41 Phase I, 147 Phase II, 30 Phase III) in 2019. Rapid advancements in the development of regenerative medicines to provide more effective solutions for chronic conditions are driving the market.

Cell therapy is one of the fastest-growing segments of the regenerative medicine domain. Novartis’s Kymriah was the first cell therapy solution offered to treat B-cell acute leukemia, which opened opportunities for this emerging treatment therapy. Moreover, RepliCel, a regenerative medicine provider, has a wide range of regenerative medicine products in the pipeline, with three products—RCH-01, RCS-01, and RCT-01—in the development phase. Further, Sernova is engaged in the development of regenerative medicine technologies and has a huge pipeline of products for conditions, such as Diabetes, Hemophilia A, and hyperthyroidism. Thus, rising adoption of regenerative medicines drives the growth of the cell therapy market.

The cell therapy market majorly consists of the players such Vericel Corporation, MEDIPOST, NuVasive, Inc., Mesoblast Limited, JCR Pharmaceuticals Co. Ltd., Smith & Nephew, Bristol-Myers Squibb Company, Cells for Cells, Stemedica Cell Technologies, Inc, and Castle Creek Biosciences, Inc. among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.

For more details visit here @ https://www.theinsightpartners.com/reports/cell-therapy-market

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: 

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi                                                     

E-mail: sales@theinsightpartners.com